S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

Clinical trial NCT01668719 · COMPLETED

Trial details

NCT number: NCT01668719
Sponsor: SWOG Cancer Research Network
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

DS Stage I Plasma Cell Myeloma DS Stage II Plasma Cell Myeloma DS Stage III Plasma Cell Myeloma

Start date: 2012-11-01
Primary completion: 2020-02-05
Enrollment: 142

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.